Summary & Overview
HCPCS J0702: Betamethasone Injection, Acetate 3 mg / Sodium Phosphate 3 mg
HCPCS Level II code J0702 denotes an injectable combination of betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg used for parenteral corticosteroid therapy. Nationally, injectable corticosteroids are a common component of outpatient musculoskeletal, rheumatologic, and certain inflammatory condition management; accurate coding for the medication itself is essential for billing, coverage determinations, and utilization tracking.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what J0702 represents clinically and operationally, common payer considerations, and the typical sites where the service is delivered. The publication outlines benchmarks for coverage and reimbursement patterns, summarizes relevant policy updates affecting injectable corticosteroids, and provides clinical context for use of a combined betamethasone acetate/sodium phosphate formulation.
The piece is aimed at billing professionals, practice managers, and policy analysts seeking a concise reference on coding, payer coverage trends, and operational implications for administering this specific betamethasone injectable. Data not available in the input will be noted where applicable, and the content focuses on national-level implications rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J0702 represents an injection formulation combining betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg. This entry denotes a packaged injectable corticosteroid preparation intended for parenteral administration.
-
Service type: Injectable corticosteroid medication administration
-
Typical site of service: Ambulatory clinics, physician offices, outpatient infusion or procedure suites, and other settings where parenteral corticosteroid injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old adult presenting to an outpatient orthopedic or pain management clinic with an acute flare of inflammatory joint disease or a localized soft-tissue inflammatory condition causing moderate to severe pain and limited function. The clinician documents a focal inflammatory process such as an acute exacerbation of osteoarthritis in a single joint (e.g., knee), a symptomatic bursitis or tendonitis, or an acute radicular flare requiring an epidural steroid injection. After clinical evaluation and review of prior therapies (oral NSAIDs, physical therapy, topical treatments), the clinician determines that a corticosteroid injection is appropriate. The facility schedules the patient for an in-office or ambulatory surgical center visit.
At the visit, informed consent is obtained, allergies and anticoagulation status are reviewed, and a targeted injection is performed using sterile technique. The medication administered is J0702 (betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg) supplied as a single-dose injection. Site of service is typically office-based procedure room, outpatient clinic, or ambulatory surgical center. Fluoroscopy or ultrasound guidance may be used when indicated (for example, intra-articular or epidural injections). Post-procedure monitoring is brief; the patient receives aftercare instructions and a plan for follow-up if pain persists or complications occur.
Typical documentation in the medical record includes indication, informed consent, medication name and HCPCS J0702, dosage, route, injection site, use of image guidance if any, lot number/expiration, patient tolerance, and plan for further management.
Coding Specifications
| Modifier | Description |
|---|